Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28003043 | 0.85 | NPC1 (0.56) | TAAR1HTR2AHTR2CALDH1A1LMNA | |
| SCHEMBL21798808 | 0.85 | TAAR1 (0.52) | TAAR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29768359 | 0.83 | PDE4A (0.52) | TAAR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15053663 | 0.83 | PDE4A (0.52) | TAAR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16099340 | 0.79 | TAAR1 (0.46) | TAAR1HTR2AHTR2CALDH1A1LMNA | |
| SCHEMBL6239161 | 0.77 | PTGES2 (0.46) | LMNA | |
| SCHEMBL23239736 | 0.77 | TAAR1 (0.66) | TAAR1HTR2AHTR2C | |
| SCHEMBL14388341 | 0.77 | TAAR1 (0.53) | TAAR1HTR2AHTR2CALDH1A1LMNA | |
| SCHEMBL12694342 | 0.77 | TAAR1 (0.78) | TAAR1HTR2AHTR2CALDH1A1 | |
| SCHEMBL11477004 | 0.77 | HTR2A (0.55) | TAAR1HTR2AHTR2CALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026611-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026611-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNA3, KCNH2, KCNJ2 | TAAR1 1252/4885PDE4A 1056/4885PDE4B 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.